News

The Manila Times18h
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian ...
MONTCO Today on MSN4d
GSK Bets Big on ‘Game-Changing’ Liver Disease Drug
GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...
PMLive5d
Madrigal’s liver disease drug Rezdiffra shows promise in compensated MASH cirrhosis
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...
Pharmaceutical Technology on MSN6d
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...
pharmaphorum6d
GSK pays $1.2bn for liver drug as it culls TIGIT programme
GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight
Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage.
Rolling Out6d
How to protect your liver from the MASH threat danger
Discover how metabolic dysfunction-associated steatohepatitis (MASH) damages your liver, its connection to common health ...